- Mirvac Group maintains its forecast for the full-year operating earnings per share (EPS) at A$0.14 to A$0.143.
- Distribution per share is still expected to be at least A$0.105.
- Mirvac has successfully completed about A$1 billion in asset sales.
- The company has sold a roughly 66% interest in 55 Pitt Street to Mitsui Fudosan.
- The total office development at 55 Pitt Street has an estimated end value of approximately A$2 billion.
- Analyst ratings: 5 buys, 4 holds, 1 sell.
A look at Mirvac Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Mirvac Group has a positive long-term outlook overall. With a high value and dividend score of 4, the company shows strong fundamentals and a commitment to rewarding shareholders. However, lower scores in growth and resilience at 2 suggest some challenges in these areas, indicating potential room for improvement in future strategies. The momentum score of 3 illustrates a moderate level of market momentum for Mirvac Group, signaling ongoing interest and activity surrounding the company.
Mirvac Group, an integrated Australian property group, boasts a well-rounded profile in both investment and development sectors. The company’s investment portfolio, Mirvac Property Trust, focuses on office, retail, and industrial assets while its development business engages in residential and commercial projects. This diversified approach positions Mirvac Group favorably in the property market, offering a mix of stability and growth potential for investors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
